SLC2A4

Summary

SLC2A4 (solute carrier family 2 member 4, HGNC:11009) is a protein-coding gene on chromosome 17p13.1, encoding Solute carrier family 2, facilitated glucose transporter member 4 (P14672). Insulin-regulated facilitative glucose transporter, which plays a key role in removal of glucose from circulation.

This gene is a member of the solute carrier family 2 (facilitated glucose transporter) family and encodes a protein that functions as an insulin-regulated facilitative glucose transporter. In the absence of insulin, this integral membrane protein is sequestered within the cells of muscle and adipose tissue. Within minutes of insulin stimulation, the protein moves to the cell surface and begins to transport glucose across the cell membrane. Mutations in this gene have been associated with noninsulin-dependent diabetes mellitus (NIDDM).

Source: NCBI Gene 6517 — RefSeq curated summary.

At a glance

• GWAS associations: 23
• Clinical variants (ClinVar): 68 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_001042

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11009
Approved symbol	SLC2A4
Name	solute carrier family 2 member 4
Location	17p13.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000181856
Ensembl biotype	protein_coding
OMIM	138190
Entrez	6517

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 2 nonsense_mediated_decay

ENST00000317370, ENST00000424875, ENST00000570783, ENST00000571308, ENST00000572485, ENST00000859022, ENST00000859023, ENST00000954706

RefSeq mRNA: 1 — MANE Select: NM_001042 NM_001042

CCDS: CCDS11097

Canonical transcript exons

ENST00000317370 — 11 exons

Exon	Start	End
ENSE00001276523	7283974	7284089
ENSE00001276531	7283738	7283862
ENSE00001276536	7283473	7283645
ENSE00001276548	7283245	7283361
ENSE00001771157	7286426	7288257
ENSE00002664276	7281718	7281967
ENSE00003580687	7284485	7284672
ENSE00003593177	7285088	7285189
ENSE00003626827	7285705	7285908
ENSE00003645804	7284835	7284939
ENSE00003667029	7284217	7284379

Expression profiles

Bgee: expression breadth ubiquitous, 127 present calls, max score 97.95.

FANTOM5 (CAGE): breadth broad, TPM avg 3.0118 / max 296.1942, expressed in 496 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
159128	2.9741	494
159129	0.0377	19

Top tissues by expression

131 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gastrocnemius	UBERON:0001388	97.95	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.95	gold quality
skeletal muscle tissue	UBERON:0001134	97.90	gold quality
apex of heart	UBERON:0002098	97.63	gold quality
muscle of leg	UBERON:0001383	96.57	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.38	gold quality
lower esophagus	UBERON:0013473	96.32	gold quality
heart left ventricle	UBERON:0002084	96.08	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.55	gold quality
right atrium auricular region	UBERON:0006631	94.25	gold quality
muscle tissue	UBERON:0002385	93.66	gold quality
muscle layer of sigmoid colon	UBERON:0035805	93.57	gold quality
heart	UBERON:0000948	92.67	gold quality
mucosa of stomach	UBERON:0001199	92.42	gold quality
urinary bladder	UBERON:0001255	86.60	gold quality
fundus of stomach	UBERON:0001160	85.82	gold quality
esophagus	UBERON:0001043	85.21	gold quality
colon	UBERON:0001155	84.94	gold quality
smooth muscle tissue	UBERON:0001135	84.91	gold quality
left uterine tube	UBERON:0001303	83.96	gold quality
omental fat pad	UBERON:0010414	82.85	gold quality
adipose tissue	UBERON:0001013	82.54	gold quality
lower esophagus mucosa	UBERON:0035834	82.12	gold quality
subcutaneous adipose tissue	UBERON:0002190	82.11	gold quality
intestine	UBERON:0000160	80.90	gold quality
transverse colon	UBERON:0001157	80.43	gold quality
prostate gland	UBERON:0002367	80.23	gold quality
tibial artery	UBERON:0007610	80.07	gold quality
popliteal artery	UBERON:0002250	80.06	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.37	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6819	yes	4508.92
E-ANND-3	yes	13.47

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ATF6, CEBPA, CEBPB, CEBPG, CNBP, DNMT1, EBF1, EPAS1, ESR1, ESR2, FOXO1, GATA6, HDAC4, HDAC5, HIF1A, KLF15, MEF2A, MEF2C, MEF2D, MLXIPL, MYC, MYOD1, NFIA, NFIC, NFKB, NR0B2, NR1H3, NR1H4, NR2F2, NR4A3, NRF1, OCLN, PAX3, PLAGL1, POU4F2, PPARA, PPARD, PPARG, PPARGC1A, PRKAA1

miRNA regulators (miRDB)

105 targeting SLC2A4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769

Literature-anchored findings (GeneRIF, showing 40)

• The insulin-sensitive glucose transporter, GLUT4, interacts physically with Daxx (PMID:11842083)
• Regulated transport of the glucose transporter GLUT4. A review. (PMID:11994746)
• observed differential response of individual isoforms GLUT1, GLUT3, & GLUT4 in neutrophils and granulocytes to hypoglycemia may represent a mechanism to protect the cells from the stress of glucose deprivation (PMID:12064911)
• The expression of the glucose transporter 4 was downregulated by up to 80% in the failing heart. (PMID:12145475)
• an effect of acid maltase deficiency extending to various vesicle systems linked to lysosomes. The enzyme defect may also affect the homoeostasis of receptors cycling through these organelles such as glucose transporter 4. (PMID:12467732)
• Data describe the expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) co-activator 1, PPAR gamma, insulin receptor substrate-1, glucose transporter isoform-4, and mitochondrial uncoupling protein-1 in adipose tissue. (PMID:12565902)
• Embedded in microvillous (maternal-facing) and basal (fetal-facing) membranes of syncytiotrophoblast, main placental barrier layer. (review) (PMID:12583599)
• upregulation of the p38 mitogen-activated protein kinase pathway might contribute to the loss of GLUT4 protein expression observed in adipose tissue from type 2 diabetic patients (PMID:12606502)
• Data suggest that GLUT4 is transported from the cell surface to a subdomain of the trans-Golgi network that is enriched in syntaxins 6 and 16 and that an acidic targeting motif in the C-terminal tail of GLUT4 plays an important role in this process. (PMID:12631717)
• The regulation of the GLUT4 gene is of special clinical interest because insulin-mediated glucose homeostasis is highly sensitive to the levels of GLUT4 protein in muscle and adipose tissue, as evidenced in this review. (PMID:12700047)
• Expression in human slow-twitch muscle fibres is not correlated with intracellular triglyceride content. (PMID:12716391)
• AICAR increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. (PMID:12716734)
• TUG traps endocytosed GLUT4 and tethers it intracellularly, and insulin mobilizes this pool of retained GLUT4 by releasing this tether (PMID:14562105)
• GLUT4 transcription activation depends on the protein-protein interaction of GEF and MEF2A (PMID:14630949)
• Strength training increases the muscle content of GLUT4. (PMID:14747278)
• ATPase inhibitors block translocation of GLUT4 in adipose cells by inhibiting formation of small insulin-responsive vesicles on donor intracellular membranes. (PMID:15166000)
• Muscle samples were obtained before the start of cycle exercise training and 24 h after the first and seventh exercise sessions. GLUT-4 protein expression was increased after 7 days of exercise training compared to baseline. (PMID:15184360)
• EHD1 and EHBP1, but not EHD2, are required for perinuclear localization of GLUT4 and reveal that loss of EHBP1 disrupts insulin-regulated GLUT4 recycling in cultured adipocytes. (PMID:15247266)
• GLUT4 is present in endometrium of normal and polycystic ovary syndrome (PCOS)subjects. hyperinsulinism and obesity seem to have negative effect on endometrial GLUT4 expression in PCOS. (PMID:15292352)
• 8 weeks of exercise training increases insulin-stimulated glucose disposal primarily by increasing GLUT4 protein expression without enhancing insulin-stimulated phosphatidylinositol 3-Kinase signaling. (PMID:15334390)
• Expression in response to exercise training in glucose intolerant elderly men. (PMID:15480742)
• The insulin-regulatable GLUT4 is expressed in the cytosol of first trimester syncytiotrophoblasts compatible with a role for GLUT4 in placental glucose transport in early pregnancy. (PMID:15528266)
• endometrial GLUT4 expression is not affected by polycystic ovary syndrome itself, whereas it is reduced by obesity in those patients. (PMID:15731326)
• Enhanced insulin-stimulated glycogen synthesis in human skeletal muscle cell culture coincides with increased GLUT4 mRNA expression following treatment with various antidiabetic agents. (PMID:15864539)
• Hyperlipidemia, exhibited as a high free fatty acid level, modulates GLUT4 gene expression in cardiac muscle via a complex mechanism including GLUT4 and the PPARgamma genes (PMID:16096283)
• Our findings that AS160 knockdown only partially releases basal GLUT4 retention provides evidence that insulin signals to GLUT4 exocytosis by both AS160-dependent and -independent mechanisms. (PMID:16213228)
• GLUT4 expression is not required for adipogenic differentiation but is necessary for full lipogenic capacity of differentiated adipocytes (PMID:16497797)
• Glut4 plasma membrane translocation and glucose uptake are induced by insulin and leptin in a human neuronal cell line by a phosphatidylinositol 3-kinase- dependent mechanism (PMID:16497805)
• In conclusion, exercise at approximately 40 and approximately 80% V(O2 peak), with total work equal, increased GLUT4 mRNA and GLUT4 protein in human skeletal muscle to a similar extent, despite differences in exercise intensity and duration. (PMID:16763099)
• results suggest that upregulation of GLUT4 gene transcription might be directly mediated by SREBP-1c in adipose tissue (PMID:16787385)
• GLUT4 and GLUT12 were predominantly expressed in type I oxidative fibers; however, GLUT5 was expressed predominantly in type II (white) fibers (PMID:16803853)
• Results suggest involvement of AMP-activated protein kinase in the control of expression of both metabolic genes, UCP3 and GLUT4, in the skeletal muscle of mice and of human newborns. (PMID:16966355)
• Adipose LPIN1 gene expression associates with basal and insulin-mediated subcutaneous adipocyte glucose transport as well as mRNA levels of glucose transporter 4. (PMID:17035674)
• Differences in GLUT4 transcription when whole adipose tissue and cell culture model systems are compared can be correlated to a posttranslational phosphorylation of the transcription factor MEF2A. (PMID:17164432)
• the luminal Vps10p domain of sortilin plays the predominant role in targeting to insulin-responsive Glut4-containing vesicles (PMID:17220298)
• enhanced GLUT4 activity was paralleled by increased transporter abundance in the plasma membrane. Disruption of the SGK1 phosphorylation site on GLUT4 ((S274A)GLUT4) abrogated the stimulating effect of SGK1. (PMID:17382906)
• Our findings implicate the muscular GLUT4 system in the glucose intolerance of liver cirrhosis by a mechanism different from that in diabetes. (PMID:17448565)
• signaling connections spanning the insulin receptor and GLUT4 [REVIEW] (PMID:17496362)
• Findings suggest that characteristic differences in the patterns of glucose uptake can exist according to the histological type and that GLUT1, GLUT3 and GLUT4 could be related to tumor angiogenesis in epithelial ovarian carcinoma. (PMID:17611657)
• Study indicated that further progress in teasing apart the GLUT4 code will require the development and application of novel and advanced technologies that can discriminate one molecule from another in the living cell. (PMID:17717074)

Cross-species orthologs

44 orthologs

Organism	Symbol	Gene ID
mus_musculus	Slc2a4	ENSMUSG00000018566
rattus_norvegicus	Slc2a4	ENSRNOG00000017226
drosophila_melanogaster	Glut3	FBGN0015230
drosophila_melanogaster	sut4	FBGN0028560
drosophila_melanogaster	sut3	FBGN0028561
drosophila_melanogaster	sut2	FBGN0028562
drosophila_melanogaster	sut1	FBGN0028563
drosophila_melanogaster	CG4607	FBGN0029932
drosophila_melanogaster	CG15406	FBGN0031517
drosophila_melanogaster	CG8837	FBGN0031520
drosophila_melanogaster	CG3285	FBGN0031522
drosophila_melanogaster	CG15408	FBGN0031523
drosophila_melanogaster	CG7882	FBGN0033047
drosophila_melanogaster	Tret1-2	FBGN0033644
drosophila_melanogaster	CG8249	FBGN0034045
drosophila_melanogaster	CG6484	FBGN0034247
drosophila_melanogaster	CG14160	FBGN0036066
drosophila_melanogaster	nebu	FBGN0036316
drosophila_melanogaster	CG1208	FBGN0037386
drosophila_melanogaster	CG14606	FBGN0037485
drosophila_melanogaster	CG14605	FBGN0037486
drosophila_melanogaster	CG6901	FBGN0038414
drosophila_melanogaster	CG17929	FBGN0038415
drosophila_melanogaster	CG17930	FBGN0038416
drosophila_melanogaster	Tret1-1	FBGN0050035
drosophila_melanogaster	CG32053	FBGN0052053
drosophila_melanogaster	CG32054	FBGN0052054
drosophila_melanogaster	CG33281	FBGN0053281
drosophila_melanogaster	CG33282	FBGN0053282
drosophila_melanogaster	Srg2	FBGN0262007
drosophila_melanogaster	CG42826	FBGN0262008
caenorhabditis_elegans		WBGENE00008730
caenorhabditis_elegans		WBGENE00010684
caenorhabditis_elegans		WBGENE00010811
caenorhabditis_elegans		WBGENE00012536
caenorhabditis_elegans		WBGENE00013074
caenorhabditis_elegans		WBGENE00016431
caenorhabditis_elegans		WBGENE00017382
caenorhabditis_elegans		WBGENE00019207
caenorhabditis_elegans		WBGENE00019547
caenorhabditis_elegans		WBGENE00019548
caenorhabditis_elegans		WBGENE00019549
caenorhabditis_elegans		WBGENE00019550
caenorhabditis_elegans		WBGENE00043980

Paralogs (13): SLC2A3 (ENSG00000059804), SLC2A9 (ENSG00000109667), SLC2A1 (ENSG00000117394), SLC2A11 (ENSG00000133460), SLC2A8 (ENSG00000136856), SLC2A5 (ENSG00000142583), SLC2A12 (ENSG00000146411), SLC2A13 (ENSG00000151229), SLC2A6 (ENSG00000160326), SLC2A2 (ENSG00000163581), SLC2A14 (ENSG00000173262), SLC2A7 (ENSG00000197241), SLC2A10 (ENSG00000197496)

Protein

Protein identifiers

Solute carrier family 2, facilitated glucose transporter member 4 — P14672 (reviewed: P14672)

Alternative names: Glucose transporter type 4, insulin-responsive

All UniProt accessions (4): P14672, F5H081, I3L1S2, I3L2R4

UniProt curated annotations — full annotation on UniProt →

Function. Insulin-regulated facilitative glucose transporter, which plays a key role in removal of glucose from circulation. Response to insulin is regulated by its intracellular localization: in the absence of insulin, it is efficiently retained intracellularly within storage compartments in muscle and fat cells. Upon insulin stimulation, translocates from these compartments to the cell surface where it transports glucose from the extracellular milieu into the cell.

Subunit / interactions. Interacts with NDUFA9. Binds to DAXX. Interacts via its N-terminus with SRFBP1. Interacts with TRARG1; the interaction is required for proper SLC2A4 recycling after insulin stimulation.

Subcellular location. Cell membrane. Endomembrane system. Cytoplasm. Perinuclear region.

Tissue specificity. Skeletal and cardiac muscles; brown and white fat.

Post-translational modifications. Sumoylated. Palmitoylated. Palmitoylation by ZDHHC7 controls the insulin-dependent translocation of GLUT4 to the plasma membrane.

Disease relevance. Type 2 diabetes mellitus (T2D) [MIM:125853] A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. The disease may be caused by variants affecting the gene represented in this entry.

Domain organisation. The dileucine internalization motif is critical for intracellular sequestration.

Miscellaneous. Insulin-stimulated phosphorylation of TBC1D4 is required for GLUT4 translocation.

Similarity. Belongs to the major facilitator superfamily. Sugar transporter (TC 2.A.1.1) family. Glucose transporter subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P14672-1	1	yes
P14672-2	2

RefSeq proteins (1): NP_001033* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002441	Glc_transpt_4	Family
IPR003663	Sugar/inositol_transpt	Family
IPR005828	MFS_sugar_transport-like	Family
IPR005829	Sugar_transporter_CS	Conserved_site
IPR020846	MFS_dom	Domain
IPR036259	MFS_trans_sf	Homologous_superfamily
IPR045263	GLUT	Family

Pfam: PF00083

Catalyzed reactions (Rhea), 1 shown:

• D-glucose(out) = D-glucose(in) (RHEA:60376)

UniProt features (84 total): helix 28, topological domain 13, transmembrane region 12, binding site 6, sequence variant 5, turn 5, modified residue 4, splice variant 2, mutagenesis site 2, chain 1, region of interest 1, short sequence motif 1, lipid moiety-binding region 1, glycosylation site 1, sequence conflict 1, strand 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
7WSM	ELECTRON MICROSCOPY	3.25
7WSN	ELECTRON MICROSCOPY	3.31

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P14672-F1	88.12	0.68

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 177; 298–299; 304; 333; 396; 404

Post-translational modifications (5): 10, 274, 486, 488, 223

Glycosylation sites (1): 57

Mutagenesis-validated functional residues (2):

Position	Phenotype
223	loss of palmitoylation.
489–490	changes subcellular location mainly to the plasma membrane.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1445148	Translocation of SLC2A4 (GLUT4) to the plasma membrane
R-HSA-189200	Cellular hexose transport
R-HSA-381340	Transcriptional regulation of white adipocyte differentiation

MSigDB gene sets: 299 (showing top): REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION, GOBP_MEMORY, GOBP_SYNAPTIC_VESICLE_LOCALIZATION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_RESPONSE_TO_ETHANOL, GOBP_CARBOHYDRATE_TRANSPORT, FREAC2_01, GOBP_COGNITION, WWTAAGGC_UNKNOWN, GOBP_BEHAVIOR, KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY, TGCGCANK_UNKNOWN, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_VESICLE_LOCALIZATION, GOBP_RESPONSE_TO_PEPTIDE

GO Biological Process (21): carbohydrate metabolic process (GO:0005975), learning or memory (GO:0007611), short-term memory (GO:0007614), long-term memory (GO:0007616), amylopectin biosynthetic process (GO:0010021), positive regulation of brain-derived neurotrophic factor receptor signaling pathway (GO:0031550), cellular response to insulin stimulus (GO:0032869), glucose homeostasis (GO:0042593), glucose import in response to insulin stimulus (GO:0044381), response to ethanol (GO:0045471), obsolete D-glucose import (GO:0046323), brown fat cell differentiation (GO:0050873), white fat cell proliferation (GO:0070343), dehydroascorbic acid transport (GO:0070837), cellular response to tumor necrosis factor (GO:0071356), cellular response to hypoxia (GO:0071456), cellular response to osmotic stress (GO:0071470), regulation of synaptic vesicle budding from presynaptic endocytic zone membrane (GO:0098694), transport across blood-brain barrier (GO:0150104), D-glucose transmembrane transport (GO:1904659), transmembrane transport (GO:0055085)

GO Molecular Function (4): D-glucose uniporter activity (GO:0015304), D-glucose transmembrane transporter activity (GO:0055056), protein binding (GO:0005515), transmembrane transporter activity (GO:0022857)

GO Cellular Component (24): multivesicular body (GO:0005771), trans-Golgi network (GO:0005802), cytosol (GO:0005829), plasma membrane (GO:0005886), clathrin-coated pit (GO:0005905), external side of plasma membrane (GO:0009897), endomembrane system (GO:0012505), vesicle membrane (GO:0012506), membrane (GO:0016020), sarcoplasmic reticulum (GO:0016529), clathrin-coated vesicle (GO:0030136), trans-Golgi network transport vesicle (GO:0030140), T-tubule (GO:0030315), cytoplasmic vesicle membrane (GO:0030659), insulin-responsive compartment (GO:0032593), sarcolemma (GO:0042383), membrane raft (GO:0045121), perinuclear region of cytoplasm (GO:0048471), extracellular exosome (GO:0070062), presynapse (GO:0098793), cytoplasm (GO:0005737), endosome (GO:0005768), cell surface (GO:0009986), vesicle (GO:0031982)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Membrane Trafficking	1
SLC-mediated transmembrane transport	1
Adipogenesis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
plasma membrane	3
memory	2
cytoplasm	2
membrane	2
primary metabolic process	1
behavior	1
cognition	1
macromolecule biosynthetic process	1
carbohydrate derivative biosynthetic process	1
amylopectin metabolic process	1
positive regulation of signal transduction	1
brain-derived neurotrophic factor receptor signaling pathway	1
regulation of brain-derived neurotrophic factor receptor signaling pathway	1
response to insulin	1
cellular response to peptide hormone stimulus	1
carbohydrate homeostasis	1
cellular response to insulin stimulus	1
D-glucose import across plasma membrane	1
response to alcohol	1
fat cell differentiation	1
fat cell proliferation	1
vitamin transport	1
response to tumor necrosis factor	1
cellular response to cytokine stimulus	1
response to hypoxia	1
cellular response to stress	1
cellular response to decreased oxygen levels	1
response to osmotic stress	1
cellular response to chemical stress	1
cellular response to abiotic stimulus	1
synaptic vesicle budding from presynaptic endocytic zone membrane	1
regulation of organelle organization	1
vascular transport	1
hexose transmembrane transport	1
hexose uniporter activity	1
D-glucose transmembrane transporter activity	1
hexose transmembrane transporter activity	1
binding	1
transporter activity	1

Protein interactions and networks

STRING

3882 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC2A4	INS	P01308	978
SLC2A4	TBC1D4	O60343	969
SLC2A4	IRS1	P35568	939
SLC2A4	VAMP2	P19065	911
SLC2A4	LNPEP	Q9UIQ6	891
SLC2A4	AKT1	P31749	886
SLC2A4	ADIPOQ	Q15848	877
SLC2A4	PPARG	P37231	872
SLC2A4	RAB10	P61026	844
SLC2A4	DAXX	Q9UER7	841
SLC2A4	LEP	P41159	838
SLC2A4	STX4	Q12846	822
SLC2A4	RHOQ	P17081	806
SLC2A4	IRS2	Q9Y4H2	805
SLC2A4	STXBP3	O00186	804

IntAct

20 interactions, top by confidence:

A	B	Type	Score
DAXX	SLC2A4	psi-mi:“MI:0915”(physical association)	0.630
SLC2A4	DAXX	psi-mi:“MI:0915”(physical association)	0.630
SLC2A4	CREB3	psi-mi:“MI:0915”(physical association)	0.560
SLC2A4	tax	psi-mi:“MI:0915”(physical association)	0.490
tax	SLC2A4	psi-mi:“MI:0915”(physical association)	0.490
ALG13	SLC2A4	psi-mi:“MI:0915”(physical association)	0.400
SLC2A4	SMAP2	psi-mi:“MI:0914”(association)	0.350
SLC2A4	TUBB2A	psi-mi:“MI:0914”(association)	0.350
SLC2A4	RAB29	psi-mi:“MI:0914”(association)	0.350
UPK2	IFT56	psi-mi:“MI:0914”(association)	0.350
SLC2A4	PTPRA	psi-mi:“MI:0914”(association)	0.350

BioGRID (85): SLC2A4 (Reconstituted Complex), DNAJC12 (Affinity Capture-MS), WDR73 (Affinity Capture-MS), SMAP2 (Affinity Capture-MS), AP1M1 (Reconstituted Complex), CREB3 (Two-hybrid), SMAP2 (Affinity Capture-MS), DNAJC12 (Affinity Capture-MS), SLC2A4 (Affinity Capture-Western), DAXX (Reconstituted Complex), DAXX (Affinity Capture-Western), SLC2A4 (Affinity Capture-Western), SLC2A4 (Reconstituted Complex), GOPC (Affinity Capture-Western), GOPC (Co-fractionation)

ESM2 similar proteins: A4ZYQ5, O35956, O57379, O62786, O62787, P0C6A1, P11166, P11167, P11168, P11169, P12336, P13355, P14142, P14246, P14672, P17809, P19357, P20303, P22732, P27674, P28568, P32037, P43427, P46896, P47842, P47843, P58351, P58352, P58353, P79365, Q07647, Q27994, Q28ES4, Q5R608, Q5RET7, Q66J52, Q6A4L0, Q6DFR1, Q6NUB3, Q6NYN7

Diamond homologs: A0A0H2VG78, A1Z8N1, A4ZYQ5, A5LGM7, A9ZSY2, A9ZSY3, B0WC46, B3MG58, B3NSE1, B4GAP7, B4HNS0, B4HNS1, B4J913, B4KR05, B4LPX5, B4MYA4, B4P624, B4QBN2, B4QBN3, C0SPB2, O04036, O04249, O34718, O44827, O52733, O62787, P0AE24, P0AE25, P0AEP1, P0AEP2, P0C6A1, P11166, P11167, P11169, P13355, P14142, P14246, P14672, P15686, P17809

SIGNOR signaling

15 interactions.

A	Effect	B	Mechanism
EXOC7	up-regulates	SLC2A4
PPARGC1A	“up-regulates quantity by expression”	SLC2A4	“transcriptional regulation”
PRKAA1	“up-regulates quantity by expression”	SLC2A4	“transcriptional regulation”
MAPK1	up-regulates	SLC2A4
INS	“up-regulates activity”	SLC2A4
AKT1	up-regulates	SLC2A4
SLC2A4	“up-regulates quantity”	glucose	relocalization
SLC2A4	“up-regulates quantity”	α-D-glucose	relocalization
TP53	“down-regulates quantity by repression”	SLC2A4	“transcriptional regulation”
AKT	up-regulates	SLC2A4
RHOQ	up-regulates	SLC2A4
TBC1D4	down-regulates	SLC2A4
SGK1	“up-regulates activity”	SLC2A4	phosphorylation
MEF2A	“up-regulates quantity by expression”	SLC2A4	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

68 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	50
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
980124	GRCh37/hg19 17p13.1(chr17:7014481-7283233)x1	Pathogenic

SpliceAI

1605 predictions. Top by Δscore:

Variant	Effect	Δscore
17:7281965:GAA:G	donor_gain	1.0000
17:7281968:G:GG	donor_gain	1.0000
17:7283230:T:TA	acceptor_gain	1.0000
17:7283234:T:TA	acceptor_gain	1.0000
17:7283238:T:TA	acceptor_gain	1.0000
17:7283242:CAG:C	acceptor_loss	1.0000
17:7283243:A:AG	acceptor_gain	1.0000
17:7283243:AG:A	acceptor_gain	1.0000
17:7283243:AGGAT:A	acceptor_gain	1.0000
17:7283244:G:GG	acceptor_gain	1.0000
17:7283244:GG:G	acceptor_gain	1.0000
17:7283244:GGA:G	acceptor_gain	1.0000
17:7283244:GGAT:G	acceptor_gain	1.0000
17:7283244:GGATG:G	acceptor_gain	1.0000
17:7283358:GAAG:G	donor_gain	1.0000
17:7283359:AAGGT:A	donor_loss	1.0000
17:7283361:GGT:G	donor_loss	1.0000
17:7283362:G:GG	donor_gain	1.0000
17:7283363:T:A	donor_loss	1.0000
17:7283642:G:GT	donor_gain	1.0000
17:7283643:A:T	donor_gain	1.0000
17:7283732:T:A	acceptor_gain	1.0000
17:7283735:CAG:C	acceptor_loss	1.0000
17:7283736:A:AG	acceptor_gain	1.0000
17:7283736:AG:A	acceptor_gain	1.0000
17:7283737:G:A	acceptor_loss	1.0000
17:7283737:G:GG	acceptor_gain	1.0000
17:7283737:GG:G	acceptor_gain	1.0000
17:7283737:GGA:G	acceptor_gain	1.0000
17:7283737:GGAAA:G	acceptor_gain	1.0000

AlphaMissense

3234 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:7283327:G:A	G39E	0.999
17:7284662:G:A	G302D	0.999
17:7284907:G:C	G330R	0.999
17:7285765:T:C	F395L	0.999
17:7285767:T:A	F395L	0.999
17:7285767:T:G	F395L	0.999
17:7285894:T:C	F438L	0.999
17:7285896:C:A	F438L	0.999
17:7285896:C:G	F438L	0.999
17:7283326:G:T	G39W	0.998
17:7283349:T:A	N46K	0.998
17:7283349:T:G	N46K	0.998
17:7284072:G:C	G183R	0.998
17:7284646:A:C	S297R	0.998
17:7284648:C:A	S297R	0.998
17:7284648:C:G	S297R	0.998
17:7284661:G:C	G302R	0.998
17:7284662:G:T	G302V	0.998
17:7285133:G:C	G356R	0.998
17:7285774:G:C	G398R	0.998
17:7285775:G:A	G398D	0.998
17:7283326:G:A	G39R	0.997
17:7283326:G:C	G39R	0.997
17:7283327:G:T	G39V	0.997
17:7283338:G:T	G43W	0.997
17:7283339:G:A	G43E	0.997
17:7283851:G:A	G146D	0.997
17:7284073:G:A	G183D	0.997
17:7284258:G:C	W202C	0.997
17:7284258:G:T	W202C	0.997

dbSNP variants (sampled 300 via entrez): RS1000383151 (17:7281724 T>G), RS1000435440 (17:7281414 T>C), RS1000718694 (17:7280386 T>C), RS1001013141 (17:7288156 G>A), RS1001247756 (17:7282078 G>A), RS1001330377 (17:7286118 C>T), RS1001446536 (17:7282663 G>A), RS1001655463 (17:7288684 G>A,T), RS1002981482 (17:7285495 A>C,G), RS1003034743 (17:7285243 G>A), RS1003735999 (17:7284241 G>A), RS1004446261 (17:7286899 T>C), RS1004795067 (17:7285432 T>C), RS1004986805 (17:7282670 G>C), RS1005337928 (17:7282331 C>T)

Disease associations

OMIM: gene MIM:138190 | disease phenotypes: MIM:125853

GenCC curated gene-disease

Mondo (1): type 2 diabetes mellitus (MONDO:0005148)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

23 associations (top):

Study	Trait	p-value
GCST001391_6	Metabolite levels	3.000000e-14
GCST001758_8	Birth weight	5.000000e-06
GCST004278_28	Pulse pressure	2.000000e-10
GCST004278_46	Pulse pressure	2.000000e-07
GCST004280_69	Diastolic blood pressure	1.000000e-13
GCST006190_4	Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	3.000000e-10
GCST006190_54	Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	3.000000e-08
GCST006192_52	Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	8.000000e-11
GCST006192_75	Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	2.000000e-12
GCST006193_37	Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	9.000000e-11
GCST006193_75	Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	9.000000e-09
GCST006195_19	Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	3.000000e-11
GCST006195_69	Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	1.000000e-12
GCST007267_235	Systolic blood pressure	7.000000e-12
GCST007928_7	Medication use (diuretics)	8.000000e-11
GCST008362_88	Birth weight	1.000000e-24
GCST008363_6	Offspring birth weight	5.000000e-11
GCST010243_87	Apolipoprotein B levels	1.000000e-10
GCST90011898_55	Alanine aminotransferase levels	2.000000e-12
GCST90011899_141	Aspartate aminotransferase levels	2.000000e-11
GCST90013405_8	Liver enzyme levels (alanine transaminase)	4.000000e-18
GCST90013663_18	Alanine aminotransferase levels	1.000000e-21
GCST90013664_44	Aspartate aminotransferase levels	9.000000e-16

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0004725	metabolite measurement
EFO:0004344	birth weight
EFO:0005763	pulse pressure measurement
EFO:0006336	diastolic blood pressure
EFO:0006527	smoking status measurement
EFO:0006335	systolic blood pressure
EFO:0009928	Diuretic use measurement
EFO:0005939	parental genotype effect measurement
EFO:0004615	apolipoprotein B measurement
EFO:0004736	aspartate aminotransferase measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D003924	Diabetes Mellitus, Type 2	C18.452.394.750.149; C19.246.300

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5874 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — Class I transporters

ChEMBL bioactivities

69 potent at pChembl≥5 of 72 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.89	IC50	13	nM	CHEMBL5661873
7.80	IC50	16	nM	CHEMBL5661842
7.80	IC50	16	nM	CHEMBL5661852
7.77	IC50	17	nM	CHEMBL5661939
7.54	IC50	29	nM	CHEMBL5661888
7.36	IC50	44	nM	CHEMBL5661849
7.21	IC50	61	nM	CHEMBL5661933
7.06	IC50	88	nM	CHEMBL5661878
7.05	IC50	90	nM	CHEMBL4089982
7.05	IC50	90	nM	CHEMBL5661828
7.03	IC50	94	nM	CHEMBL5661843
7.02	IC50	95	nM	CHEMBL5661915
6.92	IC50	120	nM	CHEMBL5661884
6.80	IC50	160	nM	CHEMBL5661913
6.77	IC50	170	nM	CHEMBL5661901
6.75	IC50	180	nM	CHEMBL5661910
6.72	IC50	190	nM	CHEMBL5661921
6.71	IC50	195	nM	CHEMBL4061928
6.70	IC50	200	nM	BAY-876
6.66	IC50	220	nM	CHEMBL5661932
6.57	IC50	270	nM	BAY-876
6.55	IC50	280	nM	CHEMBL5661859
6.55	IC50	280	nM	CYTOCHALASIN B
6.54	IC50	290	nM	BAY-876
6.47	IC50	340	nM	CHEMBL5661924
6.44	IC50	360	nM	CHEMBL5661938
6.43	IC50	370	nM	CHEMBL5661908
6.43	IC50	370	nM	CHEMBL5661847
6.42	IC50	380	nM	CHEMBL5661874
6.40	IC50	400	nM	CHEMBL5661838
6.39	IC50	410	nM	CHEMBL5661911
6.38	IC50	420	nM	CHEMBL5661918
6.30	IC50	500	nM	BAY-588
6.27	IC50	540	nM	CHEMBL5661930
6.21	IC50	610	nM	CHEMBL5661907
6.21	IC50	620	nM	CHEMBL5661934
6.17	IC50	680	nM	CHEMBL5661848
6.06	IC50	870	nM	CHEMBL5661919
6.05	IC50	890	nM	CHEMBL5661895
6.04	IC50	910	nM	CHEMBL5661844
6.04	IC50	910	nM	CHEMBL5661850
6.02	IC50	950	nM	CHEMBL5661929
6.00	IC50	1000	nM	CHEMBL5661845
5.97	IC50	1070	nM	CHEMBL5661836
5.95	IC50	1130	nM	CHEMBL5661902
5.94	IC50	1140	nM	CHEMBL5661892
5.88	IC50	1330	nM	CHEMBL5661834
5.87	IC50	1350	nM	CHEMBL5661867
5.78	IC50	1670	nM	CHEMBL5661833
5.77	IC50	1700	nM	CHEMBL4171968

PubChem BioAssay actives

61 with measured affinity, of 95 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-6-methoxyquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.0130	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-5,7-difluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.0160	uM
4-N-[1-[(5-cyanopyrazin-2-yl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.0160	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-5-methylquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.0170	uM
8-chloro-4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]quinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.0290	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-6-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.0440	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-1,7-naphthyridine-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.0610	uM
4-N-[1-[(2-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.0880	uM
(2S)-3-(2-bromophenyl)-2-[[2-(4-methoxyphenyl)acetyl]amino]-N-[(1S)-1-phenylethyl]propanamide	1425911: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake	ic50	0.0900	uM
N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-2-(1,3-thiazol-2-yl)quinoline-4-carboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.0900	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-5-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.0940	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-methylquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.0950	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-6-methylquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.1200	uM
4-N-[1-[(5-cyanothiophen-2-yl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.1600	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]quinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.1700	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-6,7-difluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.1800	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-8-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.1900	uM
(2S)-3-(4-fluorophenyl)-2-[[2-(3-hydroxyphenyl)acetyl]amino]-N-[(1S)-1-phenylethyl]propanamide	1425911: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake	ic50	0.1950	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2165766: Inhibition of human GLUT4 expressed in CHO cells measured after 15 mins by cell-titer-Glo luminescent cell viability assay	ic50	0.2000	uM
6-bromo-N-[1-[(4-fluorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]-2-(trifluoromethyl)quinoline-4-carboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.2200	uM
7-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-[1,3]thiazolo[5,4-b]pyridine-5,7-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.2800	uM
(1S,4E,6R,10R,12E,14S,15S,17S,18S,19S)-19-benzyl-6,15-dihydroxy-10,17-dimethyl-16-methylidene-2-oxa-20-azatricyclo[12.7.0.01,18]henicosa-4,12-diene-3,21-dione	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.2800	uM
6-bromo-N-[1-[2-(4-fluorophenyl)ethyl]-3,5-dimethylpyrazol-4-yl]-2-(trifluoromethyl)quinoline-4-carboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.3400	uM
N-[1-[(4-fluorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]-2,6-dimethylquinoline-4-carboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.3600	uM
7-fluoro-4-N-[5-methyl-1-[[4-(trifluoromethoxy)phenyl]methyl]-3-(trifluoromethyl)pyrazol-4-yl]quinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.3700	uM
4-N-[1-[(4-ethylphenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.3700	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-1,6-naphthyridine-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.3800	uM
4-N-[1-[(4-cyanophenyl)methyl]-3-methylpyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.4000	uM
4-N-[1-[(4-cyanophenyl)methyl]-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.4100	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methylpyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.4200	uM
4-N-[1-[(4-tert-butylphenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.5000	uM
N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-2-(2-methyl-1,2,4-triazol-3-yl)quinoline-4-carboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.5400	uM
7-fluoro-4-N-[5-methyl-1-[(3-methylphenyl)methyl]-3-(trifluoromethyl)pyrazol-4-yl]quinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.6100	uM
4-N-[1-[(5-cyano-2-pyridinyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.6200	uM
4-N-[1-[(4-cyanophenyl)methyl]-3,5-dimethylpyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.6800	uM
6-bromo-N-[1-[(4-cyano-2-fluorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]-2-(trifluoromethyl)quinoline-4-carboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.8700	uM
4-N-[1-[(4-cyano-1,3-thiazol-2-yl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.8900	uM
7-fluoro-4-N-[5-methyl-3-(trifluoromethyl)-1-[[4-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]quinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.9100	uM
N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-2-(2,4-dimethyl-1,3-thiazol-5-yl)quinoline-4-carboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.9100	uM
4-N-[1-[(3-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	0.9500	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-1,8-naphthyridine-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	1.0000	uM
7-fluoro-4-N-[5-methyl-1-[[3-(trifluoromethoxy)phenyl]methyl]-3-(trifluoromethyl)pyrazol-4-yl]quinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	1.0700	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoro-2-N-(2-morpholin-4-ylethyl)quinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	1.1300	uM
7-fluoro-4-N-[5-methyl-1-[(2-methylphenyl)methyl]-3-(trifluoromethyl)pyrazol-4-yl]quinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	1.1400	uM
4-N-[1-[(5-cyanopyrimidin-2-yl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	1.3300	uM
4-N-[1-[(3-cyano-1,2-oxazol-5-yl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	1.3500	uM
4-N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-methoxyquinoline-2,4-dicarboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	1.6700	uM
N-[[3-[2-(4-fluorophenyl)ethoxy]phenyl]methyl]-4-methoxy-N-(pyridin-4-ylmethyl)benzamide	1501205: Antagonist activity at human GLUT4 expressed in HEK293 cells transfected with GLUT1 shRNA assessed as inhibition of [3H]2-deoxy-D-glucose uptake preincubated for 5 mins followed by [3H]2-deoxy-D-glucose addition and measured after 6 mins	ic50	1.7000	uM
N-[1-[(4-cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)pyrazol-4-yl]-7-fluoro-2-(3-hydroxyazetidine-1-carbonyl)quinoline-4-carboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	1.7800	uM
6-bromo-N-[1-[(5-cyano-2-pyridinyl)methyl]-3,5-dimethylpyrazol-4-yl]-2-(trifluoromethyl)quinoline-4-carboxamide	2155045: Inhibition of human GLUT4 expressed in CHO cells assessed as reduction in glucose uptake by measuring decrease in ATP production preincubated for 20 mins followed by glucose addition and measured after 15 mins in presence of oxidative phosphorylation inhibitor rotenone by CellTiter-Glo Luminescent Cell Viability Assay	ic50	2.0200	uM

CTD chemical–gene interactions

95 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Rosiglitazone	affects cotreatment, increases expression, affects binding, decreases reaction, increases reaction	7
sodium arsenite	affects cotreatment, affects localization, decreases reaction, affects reaction, increases expression (+3 more)	6
Dexamethasone	increases reaction, affects cotreatment, increases expression, affects expression	5
bisphenol A	decreases expression, increases expression, affects cotreatment, affects binding, increases reaction	4
Benzo(a)pyrene	decreases expression, increases methylation	4
Metformin	affects reaction, decreases expression, decreases reaction, increases expression	4
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression, increases reaction	4
Tetrachlorodibenzodioxin	decreases expression, affects expression	3
Palmitic Acid	decreases reaction, affects cotreatment, affects expression, decreases expression	3
Arsenic	affects cotreatment, increases abundance, affects expression, decreases expression	2
Dichlorodiphenyl Dichloroethylene	decreases reaction, affects cotreatment, increases expression, increases reaction, decreases expression	2
Diethylhexyl Phthalate	decreases expression, decreases reaction	2
Estradiol	increases expression	2
Testosterone	affects reaction, decreases expression, affects cotreatment, increases expression	2
Aflatoxin B1	decreases expression	2
aristolochic acid I	decreases expression	1
STF-31	affects cotreatment, decreases expression, decreases reaction	1
AKT activator SC79	affects cotreatment, affects localization, decreases reaction	1
propionaldehyde	increases expression	1
2,4,5,2’,4’,5’-hexachlorobiphenyl	decreases reaction, affects cotreatment, decreases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	affects cotreatment, decreases expression, decreases reaction	1
3-methyladenine	increases reaction, decreases expression	1
ursodoxicoltaurine	decreases reaction, decreases expression	1
benazol P	affects expression	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression	1
prochloraz	decreases expression	1
arsenic disulfide	decreases expression	1

ChEMBL screening assays

24 unique, capped per target: 23 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1103148	Binding	Inhibition of GLUT4	Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARalpha activation activity. — J Nat Prod
CHEMBL5209607	Functional	Inhibition of the Glucose Transporter (GLUT4, SLC2A4) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A4 WT-OE cells (PubChe	Flow cytometry transport assay for SLC2A4 using HEK293 JumpIN TRex SLC2A4 WT-OE cells

Cellosaurus cell lines

6 cell lines: 6 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2FT	Abcam HeLa SLC2A4 KO	Cancer cell line	Female
CVCL_D4T2	HuH7-SLC2A4-KO-c1	Cancer cell line	Male
CVCL_D4T3	HuH7-SLC2A4-KO-c2	Cancer cell line	Male
CVCL_D4VR	LS180-SLC2A4-KO-c5	Cancer cell line	Female
CVCL_D4VS	LS180-SLC2A4-KO-c7	Cancer cell line	Female
CVCL_D8VB	Ubigene HCT 116 SLC2A4 KO	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00006163	PHASE4	COMPLETED	Computer-assisted Diabetes Self-management Interventions
NCT00036504	PHASE4	COMPLETED	Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin
NCT00044460	PHASE4	COMPLETED	Efficacy and Safety In Poorly Controlled Type 2 Diabetics
NCT00095446	PHASE4	COMPLETED	NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
NCT00101751	PHASE4	COMPLETED	INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study
NCT00110370	PHASE4	COMPLETED	Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes
NCT00110448	PHASE4	COMPLETED	Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial
NCT00118950	PHASE4	COMPLETED	Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
NCT00118963	PHASE4	COMPLETED	Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
NCT00121966	PHASE4	COMPLETED	South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus
NCT00123604	PHASE4	COMPLETED	Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes
NCT00123643	PHASE4	COMPLETED	Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
NCT00124397	PHASE4	COMPLETED	Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)
NCT00129233	PHASE4	COMPLETED	Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
NCT00133718	PHASE4	COMPLETED	A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control
NCT00135070	PHASE4	TERMINATED	Hospital In-Patient Insulin Study
NCT00141232	PHASE4	COMPLETED	Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
NCT00144144	PHASE4	UNKNOWN	A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes
NCT00149331	PHASE4	COMPLETED	The Effects of Two Education Strategies About Insulin on Patient Preferences and Perceptions About Insulin Therapy
NCT00162357	PHASE4	COMPLETED	Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty
NCT00174681	PHASE4	COMPLETED	Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
NCT00174824	PHASE4	COMPLETED	Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients
NCT00177398	PHASE4	COMPLETED	Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings
NCT00179400	PHASE4	COMPLETED	The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans
NCT00184561	PHASE4	COMPLETED	Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
NCT00184626	PHASE4	COMPLETED	Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
NCT00191178	PHASE4	COMPLETED	Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes
NCT00191282	PHASE4	COMPLETED	Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
NCT00191464	PHASE4	COMPLETED	Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
NCT00192803	PHASE4	UNKNOWN	Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs
NCT00202033	PHASE4	COMPLETED	Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes
NCT00205660	PHASE4	COMPLETED	Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
NCT00212290	PHASE4	COMPLETED	Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
NCT00212303	PHASE4	COMPLETED	Exercise Training in Type 2 Diabetes and Hypertension
NCT00225342	PHASE4	WITHDRAWN	Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina
NCT00238472	PHASE4	COMPLETED	A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
NCT00239538	PHASE4	COMPLETED	SMOOTH - Blood Pressure Control in Diabetic/Obese Patients
NCT00240253	PHASE4	COMPLETED	A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
NCT00240422	PHASE4	COMPLETED	Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes
NCT00241085	PHASE4	COMPLETED	Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus